FREMONT, Calif., May 6 /PRNewswire/ -- Optovue, a pioneer in fourier/spectral-domain optical coherence tomography (OCT), has announced fiscal year-end results for 2009 compared to fiscal year 2008. Despite the down economy, eye care clinicians proved that the right combination of clinical utility and clinical value is still the best package.
"Our customers around the world provided a 19% revenue increase for 2009 over 2008," stated Gordon Wong, Vice President of Finance for Optovue. "We have continuing strong support by representatives and distributor's world-wide, and all regions including the US are up significantly from 2008. The first fiscal quarter of 2010 demonstrated still another significant increase over 2009 numbers. The trend is clearly demonstrating that the clinical package offered by Optovue products is still highly desirable when faced with a number of product options."
About RTVue and iVue
RTVue was the first FDA cleared Fourier domain (also known as spectral domain) OCT launched in the United States, and also the first OCT cleared by the U.S. Food and Drug Administration for both corneal and retinal imaging. The iVue is the compact fourier-domain version of the RTVue OCT, offering the same scanning speed and resolution as the larger system, that includes scanning and reports for retina, retina nerve fiber and cornea assessment by the clinician.
About Optovue (www.optovue.com / www.ivueoct.com)
Optovue Incorporated is a privately-held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease. Optovue has achieved widespread market success through a combination of unique data analysis design, a reputation for excellent customer service, and rapid innovation of its technology in response to physician feedback. The company is headquartered in Fremont, CA, with operations in Carlsbad, CA, and European operations in Heidelberg, Germany.